Spermosens Valuation
Is SPERM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of SPERM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate SPERM's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate SPERM's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for SPERM?
Key metric: As SPERM is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is SPERM's PB Ratio? | |
|---|---|
| PB Ratio | 0.2x |
| Book | SEK 21.97m |
| Market Cap | SEK 3.29m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | n/a |
| Enterprise Value/EBITDA | -0.5x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does SPERM's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.9x | ||
DIABIO Diagonal Bio | 0.5x | n/a | SEK 13.4m |
SCOL Scandion Oncology | 0.5x | 69.7% | SEK 17.9m |
LIDDS LIDDS | 1.9x | n/a | SEK 14.4m |
EURI B European Institute of Science | 0.8x | n/a | SEK 4.0m |
SPERM Spermosens | 0.2x | n/a | SEK 3.3m |
Price-To-Book vs Peers: SPERM is good value based on its Price-To-Book Ratio (0.2x) compared to the peer average (0.9x).
Price to Book Ratio vs Industry
How does SPERM's PB Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Book vs Industry: SPERM is good value based on its Price-To-Book Ratio (0.2x) compared to the Swedish Biotechs industry average (2.4x).
Price to Book Ratio vs Fair Ratio
What is SPERM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 0.2x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate SPERM's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
PMD Device Solutions
SEK 36.3m
A digital medical device company, develops and sells respiratory monitoring solutions in Ireland.
PMDS
SEK 1.40
7D
-6.0%
1Y
n/a
Swedish Orphan Biovitrum
SEK 99.5b
An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia.
SOBI
SEK 289.80
7D
-10.9%
1Y
20.1%
Corline Biomedical
SEK 148.7m
Develops, manufactures, and markets heparin based solutions to enhance kidney transplantation, cell therapies, and regenerative medicine applications.
CLBIO
SEK 6.92
7D
4.8%
1Y
-40.3%